Context: Vitamin D deficiency in obesity has been linked to insulin resistance. However, studies that examined the association between plasma 25-hydroxyvitamin D 3 were not related to tissue-specific insulin sensitivity. Interestingly, SAT VDR mRNA was negatively associated with AT insulin sensitivity (b = 20.207; P = 0.025).
suggested to contribute to obesity-related metabolic disorders, such as insulin resistance and type 2 diabetes (4, 5) . However, evidence from human observational data are not consistent. Recent studies have shown a negative association between plasma or serum vitamin D 25(OH)D 3 levels and whole-body insulin resistance, as estimated from the homeostatic model for insulin resistance, which was independent of body mass index (BMI) in both men and women (6, 7) . In contrast, other studies have shown no association between serum 25(OH)D 3 and insulin resistance (homeostatic model for insulin resistance/ HOMA-IR) in humans with obesity (8, 9) . It has been hypothesized that mainly adiposity itself may determine the observed relationship between plasma vitamin D deficiency and insulin resistance because of sequestration of vitamin D in the enlarged AT mass (10) . Furthermore, it has been proposed that the difference in vitamin D concentrations between lean and individuals with obesity may be explained by volumetric dilution in obesity, with body weight explaining 13% of the variance in vitamin D concentrations (11) . Finally, it has been postulated that altered vitamin D metabolism in AT may contribute to vitamin D deficiency and insulin resistance (12) .
Indeed, AT is actively involved in vitamin D metabolism, which is underlined by the expression of vitamin D-metabolizing enzymes [cytochrome 450 (CYP)] and the vitamin D receptor (VDR) in AT (13) . VDR belongs to the nuclear receptor family and mediates effects of vitamin D at the gene transcription level (14) . In murine adipocytes, the active vitamin D metabolite, 1,25(OH) 2 D 3 may increase sirtuin 1 and the oxidized form of nicotinamide adenine dinucleotide/reduced form of nicotinamide adenine dinucleotide, thereby affecting cellular energy metabolism (15) . Furthermore, it has previously been reported that VDR expression is similar in visceral AT (VAT) and subcutaneous AT (SAT) of individuals with obesity (16) , although the expression of vitamin D-metabolizing enzymes (CYP) was decreased in SAT of individuals with obesity (16) . Currently, it is not clear whether VDR expression is altered in the obese insulin-resistant state and whether alterations in AT expression of VDR or vitamin D-metabolizing enzymes relate to vitamin D deficiency and/or AT insulin resistance. Recent meta-analyses have shown that vitamin D supplementation had no significant effects on wholebody insulin resistance and insulin secretion in individuals who are overweight/obese (17, 18) . Taken together, the contribution of vitamin D deficiency to whole-body and tissue-specific insulin resistance remains to be established, and it is unclear whether a possible association is independent of BMI and/or body fat percentage (19, 20) . Moreover, most studies that examined the association between vitamin D and insulin sensitivity did not use the gold-standard hyperinsulinemic euglycemic clamp to determine insulin sensitivity (21) . Additionally, most of the studies on the relationship between vitamin D and insulin sensitivity have measured the inactive metabolite of vitamin D, 25(OH)D 3 (7, 9, 22) 
Participants and Methods

Participants
The study participants were men and women of Caucasian ethnicity, recruited at the Maastricht University Medical Center, Maastricht, Netherlands. Inclusion and exclusion criteria of these participants are described elsewhere in more detail (23, 24) . The participants gave written informed consent, and the local medical ethical committee of Maastricht University Medical Center reviewed and approved the study.
Two-step hyperinsulinemic-euglycemic clamp
A two-step hyperinsulinemic-euglycemic clamp combined with a [6,6-2 H 2 ]-glucose tracer (Cambridge Isotope Laboratories) was performed to analyze the insulin-mediated suppression of free fatty acids (representing AT insulin sensitivity) (25) , insulin-stimulated rate of disappearance (Rd) of glucose (peripheral/muscle insulin sensitivity), and insulin-mediated suppression of endogenous glucose production (EGP) (hepatic insulin sensitivity) (26 (24) . Blood samples were taken from a superficial dorsal hand vein, which was arterialized by using a hot box (;50°C).
AT biopsy and analysis
An abdominal subcutaneous AT biopsy sample was taken under local anesthesia after an overnight fast, as described before (23) . The AT sample was washed in sterile saline, immediately frozen in liquid nitrogen, and maintained at 280°C until further analysis. For RNA isolation, the tissue was placed in Trizol (Qiagen) and then mixed by means of an Ultra Turrax homogenizer (Polytron). Total RNA was extracted by using a phenol-chloroform extraction method, as described in more detail elsewhere (16) .
Adipose tissue gene expression
For quantitative RT-PCR, cDNA was generated by using an iScript cDNA synthesis kit, according to the instructions of the manufacturer (Bio-Rad Laboratories). PCR master mix, containing the specific primers, was added and real-time quantification of genes was performed by SYBR-green reverse transcription RT-PCR assay (Bio-Rad iQ SYBR green mix) using a MyIQ Real time PCR cycler (Bio-Rad). The primer pairs that were used are described in Supplemental Table 1 . 18S was used as a housekeeping gene, and data were calculated by using the delta CT method (16) .
Biochemical analysis
Blood was collected into prechilled tubes and centrifuged at 1000 g, and plasma was snap-frozen and stored at ;80°C until analyses. Tracer enrichment of rate of disappearance and EGP were determined by using gas chromatography-mass spectrometry (26) . Plasma glucose and free fatty acids were determined by using commercial available colorimetric assays on a Cobas Fara auto-analyzer (Roche). Plasma insulin was measured with a double-antibody radioimmunoassay (Millipore). Plasma concentrations of 25(OH)D 3 and 1,25(OH) 2 D 3 were determined by using liquid chromatography-tandem mass spectrophotometry, as described before (29) .
Statistical analysis
All continuous variables were checked for normal distribution. Variables with a skewed distribution were square root transformed (plasma vitamin D concentration and SAT VDR mRNA) or natural logarithmically transformed (SAT vitamin D enzymes, CYP2J2, CYP27A1, CYP27B1, and CYP24A1) to satisfy condition of normality.
First, simple regression analysis was performed with plasma vitamin D metabolites or VDR and vitamin D-metabolizing enzymes as dependent variables and BMI as an independent variable. Subsequently, multiple regression analysis was performed with age and sex added as independent variables.
Second, simple regression analysis was performed with hepatic, peripheral, or AT insulin sensitivity as dependent variables and plasma 25 ratio as independent variables (model 1). Next, BMI, age, and sex were added to the model as independent variables (models 2 to 4). Finally, simple regression analysis was performed to relate SAT VDR gene expression and AT insulin sensitivity. Subsequently, multiple regression analysis was conducted to test whether SAT VDR gene expression might relate to AT insulin sensitivity, independent of age, BMI, and sex. Interaction between covariates in the multiple regression analyses was also tested, and no interaction was found. All data were analyzed by using SPSS for Mac, version 22.0 (IBM Inc.) and statistical significance was set at P , 0.05.
Results
Characteristics of study participants
Anthropometric and metabolic characteristics for all participants are presented in Table 1 Table 2) .
Association between BMI and vitamin D-related gene expression in SAT BMI was positively associated with SAT VDR gene expression (std b = 0.223; 95%CI, 0.00 (0.44), P = 0.047 (Table 3) . It is well established that VDR expression is regulated by 1,25(OH) 2 D 3 (31) . However, the strength of the association between BMI and AT VDR gene expression did not change (std b = 0.213; 95% CI, 20.11 to 0.44; P = 0.062) after adjustment for plasma 1,25(OH) 2 D 3 (active metabolite), age, and sex. No significant associations were found between BMI and SAT expression of vitamin D metabolizing enzymes (CYP2J2, CYP27A1, CYP27B1, CYP24A1) (Supplemental Table 2 ).
Plasma vitamin D 25(OH)D 3 and SAT expression of VDR and vitamin D enzymes
Next, we investigated the relationship between plasma 25(OH)D 3 levels and the expression of VDR and enzymes related to vitamin D metabolism in SAT. Abdominal SAT expression of VDR and vitamin D-metabolizing enzymes was not associated with plasma 25(OH)D 3 level (Supplemental Table 3 ). Additionally, we investigated whether the negative relationship between BMI and plasma 25(OH)D 3 may be mediated by alteration in AT expression of VDR or vitamin D-metabolizing enzymes. As indicated in Table 4 , further adjustment for SAT VDR expression or SAT vitamin D-metabolizing enzymes did not significantly alter the relationship between BMI and plasma 25(OH)D 3 .
Plasma vitamin D metabolite levels and tissue-specific insulin sensitivity
Neither plasma 25(OH)D 3 (inactive metabolite) nor plasma 1,25(OH) 2 D 3 (active metabolite) nor the active/ inactive metabolite ratio was associated with hepatic, peripheral, or AT insulin sensitivity, as shown in Table 5 .
SAT VDR, vitamin D-metabolizing enzyme expression, and AT insulin sensitivity
Finally, we examined the association between AT VDR gene expression and AT insulin sensitivity. SAT VDR expression was negatively correlated with AT insulin sensitivity (std b = 20.207; 95% CI, 20.39 to 20.03; P = 0.025), which was independent of age, sex, and BMI (Table 6) . No associations were found between SAT expression of vitamin D2metabolizing enzymes and AT insulin sensitivity (data not shown).
Discussion
In the current study, we demonstrated that (1) (29) . It has been postulated that these low plasma 25(OH)D 3 levels in persons with obesity may be partly explained by increased blood volume due to the larger body size (i.e., volumetric dilution) or sequestration of vitamin D in the expanded body fat depot (10, 11) . However, vitamin D may affect skeletal muscle mass (34) as well as bone mass (35) . Therefore, it is important to distinguish the relationship between vitamin D and BMI or AT mass.
Unfortunately, in the current study we did not assess body composition. Therefore, it is unclear whether the observed association between vitamin D and BMI reflects the relationship with AT mass per se. The latter needs to be investigated in more detail in future research. Alterations in AT vitamin D metabolism might be implicated in plasma vitamin D deficiency (36) . However, in the current study, we did not find a significant association between SAT VDR gene expression and plasma 25(OH)D 3 concentration. Furthermore, the expression of the vitamin D-metabolizing enzymes (CYPs) in SAT was not significantly related to plasma 25(OH)D 3 levels. In contrast, previous research has shown a positive correlation between CYP27A1 expression in VAT and plasma 25(OH)D 3 (16) . In addition, Wamberg et al. (16) showed that obesity is characterized by a decreased expression of the 25-hydroxylase CYP2J2 and the 1a-hydroxylase CYP27B1 in SAT, whereas the catabolic CYP24A1 does not differ between women who are lean and women with obesity. However, the expression of catabolic CYP24A1 increased after weight loss (16) , suggesting a higher vitamin D turnover in the SAT of persons with obesity after weight loss. We cannot exclude that gene expression of vitamin D-metabolizing enzymes may differ between the SAT and VAT (16) , which might partly explain the lack of association between plasma 25(OH)D 3 with SAT gene expression in the current study. In the current study, SAT VDR expression was positively associated with BMI, which is in line with previous findings in VAT (7) , indicating that VDR expression is increased in both SAT and VAT in obesity. However, the physiologic relevance of this upregulation needs to be elucidated in future research. The SAT is by far the body's largest fat depot, and an important mass effect on vitamin D metabolism is therefore more likely compared with VAT.
Recent meta-analyses have shown no effect of oral vitamin D 3 supplementation on glucose metabolism and insulin resistance/secretion (17, 37) . Here, we found that plasma 25(OH)D 3 , 1,25(OH) 2 D 3 concentration, and the 1,25(OH) 2 D 3 /25(OH)D 3 ratio were not significantly associated with hepatic, peripheral, or AT insulin sensitivity in men and women who are overweight/obese. Taken together, our data suggest that plasma vitamin D deficiency is not related to insulin resistance in men and women with overweight/obesity, assessed by using the gold standard hyperinsulinemic-euglycemic clamp. Finally, we observed that higher SAT VDR gene expression was associated with lower AT insulin sensitivity independent of BMI, age, and sex and explained 14% of the variance in AT insulin sensitivity. Recent study has suggested that the association between insulin resistancerelated diseases and VDR polymorphisms was more pronounced in dark-pigmented and Asian people but not in Caucasians with white skin (38) . However, it needs to be investigated whether these genetic and our observed transcriptional differences also translate into functional changes at the protein level. Furthermore, it has been shown that VDR mRNA expression is positively associated with local inflammation in human SAT and VAT (39) . However, further studies are needed to investigate whether the observed association between SAT VDR expression and AT insulin sensitivity is at least partly explained by AT inflammation.
In conclusion, obesity is associated with lower plasma 25(OH)D 3 (inactive metabolite), but not with plasma 1,25(OH) 2 ratio were not associated with hepatic, AT, and peripheral insulin sensitivity in men and women who are overweight/ obese. Interestingly, SAT VDR gene expression was negatively associated with AT insulin sensitivity, and future studies are needed to unravel the molecular mechanisms by which nuclear and membrane-bound VDR interact with insulin action in abdominal SAT.
